

# Multiple Sclerosis Therapeutics: Market Research Report

<https://marketpublishers.com/r/M171B48860CEN.html>

Date: April 2010

Pages: 430

Price: US\$ 3,950.00 (Single User License)

ID: M171B48860CEN

## Abstracts

This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US\$ Billion.

The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. MARKET HIGHLIGHTS

Market Snapshots  
Market Drivers  
Market Restraints  
Major Players

#### 2. MARKET OVERVIEW

Increasing Prevalence of Multiple Sclerosis

**Table 1.** World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

**Table 2.** Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart)

MS Therapeutics in the Market  
Key Multiple Sclerosis Drugs  
Interferon Drugs  
Beta Interferon Drugs in Multiple Sclerosis Treatment  
Non-Interferon Drugs  
Non-Interferon Drugs in Multiple Sclerosis Treatment  
High Unmet Need and Rich Pipeline to Expand MS Market  
Challenges Ahead

### **3.MARKET TRENDS**

Interferon-based Drugs Dominate Multiple Sclerosis Market

Sales Dip Inevitable for Current Therapies

Tough Times Ahead for Betaseron

Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies

Competitive Landscape

**Table 3.** Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

### **4.MULTIPLE SCLEROSIS - DRUG PIPELINE**

Recent Clinical Trial Activity – An Overview

Drugs Under Development for Treating Multiple Sclerosis

FTY 720 (Fingolimod)

Mylinax

Laquinimod

Alemtuzumab

Teriflunomide

BG-12 (Oral Fumarate)

#### **MN-166**

Rituxan/MabThera (Rituximab)

Vaccines for Multiple Sclerosis

### **5.PRODUCT OVERVIEW**

Definition

Causes of Multiple Sclerosis

Different Forms of Multiple Sclerosis

Pathology

### **6.RECENT INDUSTRY ACTIVITY**

Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple

## Sclerosis

Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA

Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS

Novartis Obtains FDA Approval for Extavia

Merck Serono Collaborates with Brigham and Women's Hospital to Extend Multiple Sclerosis Research

Merck Serono Announces Encouraging Phase III Results of Oral Mylinax

Merck Serono Acquires Rights to Apitope's Multiple Sclerosis Approach

Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod

Genzyme Signs an Agreement with Bayer Healthcare

EMD Serono to Set Up Research Facility in Massachusetts

EMD Serono Enters into a Partnership with Fast Forward

Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI®

Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a

Bayer Schering Pharma Receives SFDA of China Approval for Betaferon®

Merck Serono Signs an Agreement with Bionomics

Orasi Medical Establishes New Office in Tokyo

Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis

Kineta Acquires Novel Therapeutic Compounds from Airmid

MediciNova Enters into Agreement with Avigen

Biogen Idec Takes Over Facet Biotech

Teva Pharmaceutical Industries to Take over CoGenesys

Merck Serono Introduces RebiSmart™ Electronic Injection Device

Bayer to Launch Betaferon Titration Pack

MediciNova Announces Phase II Clinical Trial Results of MN-166

The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services

Acorda Therapeutics Takes Over Neurorecovery

Bayer to Introduce 30-Gauge Needle for Betaferon®

Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12

Bayer Acquires Biologics Manufacturing Plant from Novartis

## 7.FOCUS ON SELECT PLAYERS

Bayer Schering Pharma AG (Germany)

Biogen Idec Inc. (US)

Elan Pharmaceuticals, Inc. (US)

Genzyme Corp. (US)

Merck Serono SA (Switzerland)  
Novartis AG (Switzerland)  
Sanofi-Aventis SA (France)  
Teva Pharmaceuticals Industries Limited (Israel)

## **8. GLOBAL MARKET PERSPECTIVE**

**Table 4.** World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 5.** World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

**Table 6.** World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs – Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 7.** World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs – Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

## **III. MARKET**

### **1. THE UNITED STATES**

#### **A. MARKET ANALYSIS**

Overview

**Table 8.** US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Strategic Corporate Developments

Key Players

Biogen Idec, Inc.

Elan Pharmaceuticals, Inc.

EMD Serono, Inc.

Genzyme Corp.

## **B. MARKET ANALYTICS**

**Table 9.** US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2.JAPAN**

### **A. MARKET ANALYSIS**

Overview

**Table 10.** Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Strategic Corporate Development

## **B. MARKET ANALYTICS**

**Table 11.** Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **3.EUROPE**

### **A. MARKET ANALYSIS**

Overview

**Table 12.** Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Low Penetration to Fuel Growth in European MS DMDs Market

Oral Medication for MS in Near Future

Strategic Corporate Development

Key Players

Bayer Schering Pharma AG (Germany)

Merck Serono SA (Switzerland)

Novartis AG (Switzerland)

Sanofi-Aventis SA (France)

## **B. MARKET ANALYTICS**

**Table 13.** European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **4.REST OF WORLD**

### **A. MARKET ANALYSIS**

Overview

Increasing Incidence of Multiple Sclerosis in Canada

Strategic Corporate Developments

Key Player

Teva Pharmaceuticals Industries Limited (Israel)

### **B. MARKET ANALYTICS**

**Table 14.** Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US\$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 45 (including Divisions/Subsidiaries - 51)

Region/Country/Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle East



## I would like to order

Product name: Multiple Sclerosis Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/M171B48860CEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M171B48860CEN.html>